HPLC MS Method for Analysis of Zidesamtinib on Chromni Column

HPLC Method for Analysis of Zidesamtinib on Chromni Column by SIELC Technologies

High Performance Liquid Chromatography (HPLC) Method for Analysis of Zidesamtinib.

Zidesamtinib is an anti-cancer medication with the chemical formula C22H22FN7O. It is primarily used to treat non-small cell lung cancer and works as a kinase inhibitor.

Zidesamtinib can be retained and analyzed using the Chromni stationary phase column. The analysis utilizes a gradient method with a simple mobile phase consisting of water and acetonitrile (MeCN) and ethanol. Detection is performed using LC MS.

Condition

ColumnChromni, 3.2 x 100 mm, 3 µm, 100 A, dual ended
Mobile PhaseGradient MeCN/H2O
BufferAmAc pH 5.0 – 10 mM
Flow Rate0.5 ml/min
DetectionLC MS ESI SIM 420 [M+H] +

Description

Class of CompoundsDrugs
Analyzing CompoundsZidesamtinib

Application Column

Chromni

Column Diameter: 3.2 mm
Column Length: 100 mm
Particle Size: 3 µm
Pore Size: 100 A
Column options: dual ended

Add to cart
Application Analytes:
Zidesamtinib
Application Detection:
LC MS Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.